1.
Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care
by KALAYJIAN, Robert C
AIDS (London), 2012, Vol.26 (15), p.1907-1915
2.
Pre-vaccine plasma levels of soluble inflammatory indices negatively predict responses to HAV, HBV, and tetanus vaccines in HCV and HIV infection
by Shive, Carey L
Vaccine, 2018-01-25, Vol.36 (4), p.453-460
3.
Suppression of HIV-1 replication by antiretroviral therapy improves renal function in persons with low CD4 cell counts and chronic kidney disease
by KALAYJIAN, Robert C
AIDS (London), 2008, Vol.22 (4), p.481-487
4.
Spectrum of excess mortality due to carbapenem-resistant Klebsiella pneumoniae infections
by Hauck, C
Clinical microbiology and infection, 2016-06, Vol.22 (6), p.513-519
5.
Older HIV-infected patients on antiretroviral therapy have B-cell expansion and attenuated CD4 cell increases with immune activation reduction
by KALAYJIAN, Robert C
AIDS (London), 2013, Vol.27 (10), p.1563-1573
6.
Tigecycline therapy for carbapenem-resistant Klebsiella pneumoniae (CRKP) bacteriuria leads to tigecycline resistance
by van Duin, D
Clinical microbiology and infection, 2014-12, Vol.20 (12), p.O1117-O1120
7.
Age-Related Changes in Plasma Concentrations of the HIV Protease Inhibitor Lopinavir
by CRAWFORD, Keith W
AIDS research and human retroviruses, 2010, Vol.26 (6), p.635-643
8.
Thrombosis of the aorta caused by mucormycosis
by Kalayjian, R C
Southern medical journal (Birmingham, Ala.), 1988-09, Vol.81 (9), p.1180-1181
9.
Nadir CD4+ T-cell count and numbers of CD28+ CD4+ T-cells predict functional responses to immunizations in chronic HIV-1 infection
by LANGE, Christoph G
AIDS (London), 2003, Vol.17 (14), p.2015-2023
10.
Efficacy of a nucleoside-sparing regimen of darunavir/ ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262)
by TAIWO, Babafemi
AIDS (London), 2011, Vol.25 (17), p.2113-2122
